Platelet Glycoprotein IIb/IIIa Inhibition with Coronary Stenting for Acute Myocardial Infarction

Coronary stenting and antiplatelet therapy both play an important part in interventional cardiology, 1 – 3 and the emergence and development of both therapies have been closely associated. 4 – 7 The combination of ticlopidine and aspirin enhances the benefit of coronary stenting by reducing acute stent thrombosis, and new agents such as platelet glycoprotein IIb/IIIa inhibitors 8 limit ischemic complications in patients undergoing balloon angioplasty 9 – 12 or stent implantation. 13 , 14 However, despite the potential link between fibrinogen and restenosis, blockade of glycoprotein IIb/IIIa has not been shown to alter the frequency of restenosis as determined by angiography or echocardiography. 15 , 16 There are few data . . .